A5024509683- Bacterial Infections and Vaccines
- Pneumonia and Respiratory Infections
- Vaccine Coverage and Hesitancy
- Virology and Viral Diseases
- Immune responses and vaccinations
- Respiratory viral infections research
- Influenza Virus Research Studies
- Infective Endocarditis Diagnosis and Management
- Peptidase Inhibition and Analysis
- Hepatitis Viruses Studies and Epidemiology
- Microbial infections and disease research
- Viral gastroenteritis research and epidemiology
- Viral Infections and Outbreaks Research
- Data-Driven Disease Surveillance
- Public Health Policies and Education
- Antibiotic Resistance in Bacteria
- Infectious Encephalopathies and Encephalitis
- Animal Disease Management and Epidemiology
Centers for Disease Control and Prevention
2011-2024
Center for Global Health
2023-2024
AID Atlanta
2022
Center for Surveillance, Epidemiology, and Laboratory Services
2021-2022
National Center for Immunization and Respiratory Diseases
2009-2019
United States Department of Health and Human Services
2015
Union Economique et Monétaire Ouest Africaine
2014
Centre Hospitalier Universitaire Yalgado Ouédraogo
2014
Ministère De La Santé
2014
Meningitis Now
2011
In January 2005, a quadrivalent (serogroups A, C , Y, and W-135) meningococcal conjugate vaccine was licensed for use in adolescents. This report describes the epidemiologic features of disease United States from 1998 through December 2007, before during implementation adolescent vaccination.Data were collected active surveillance invasive Neisseria meningitidis conducted Active Bacterial Core (ABCs) sites 1998-2007. Isolates cases serogrouped at ABCs site confirmed Centers Disease Control...
Measles is a highly contagious, vaccine-preventable disease that requires high population immunity for transmission to be interrupted. All six World Health Organization regions have committed eliminating measles; however, no region has achieved and sustained measles elimination. This report describes elimination progress during 2000-2022. During 2000-2019, estimated coverage worldwide with the first dose of measles-containing vaccine (MCV) increased from 72% 86%, then declined 81% in 2021...
In 2012, the World Health Assembly endorsed Global Vaccine Action Plan,* with objective of eliminating measles
All six World Health Organization (WHO) regions have committed to eliminating measles.* The Immunization Agenda 2021-2030 (IA2030)
Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae are important causes of meningitis other infections, rapid, sensitive, specific laboratory assays critical for effective public health interventions. Singleplex real-time PCR have been developed to detect N. meningitidis ctrA, H. influenzae hpd, S. lytA serogroup-specific genes in the cap locus serogroups A, B, C, W135, X, Y. However, assay sensitivity Y is low. We aimed improve develop multiplex reduce time cost....
We report on three cases of meningococcal disease caused by ciprofloxacin-resistant Neisseria meningitidis, one in North Dakota and two Minnesota. The were the same serogroup B strain. To assess local carriage resistant N. we conducted a pharyngeal-carriage survey isolated strain from asymptomatic carrier. Sequencing gene encoding subunit A DNA gyrase (gyrA) revealed mutation associated with fluoroquinolone resistance suggests that was acquired means horizontal transfer commensal lactamica....
Real-time PCR (rt-PCR) is a widely used molecular method for detection of Neisseria meningitidis (Nm). Several rt-PCR assays Nm target the capsule transport gene, ctrA. However, over 16% meningococcal carriage isolates lack ctrA, rendering this gene ineffective at identification sub-population isolates. The Cu-Zn superoxide dismutase sodC, found in but not other species. To better identify Nm, regardless genotype or expression status, sodC-based TaqMan assay was developed and validated....
Worldwide, measles remains a major cause of disease and death; the highest incidence is in World Health Organization African Region (AFR). In 2011, 46 AFR member states established goal regional elimination by 2020; this report describes progress during 2017-2021. Regional coverage with first dose measles-containing vaccine (MCV) decreased from 70% 2017 to 68% 2021, number countries ≥95% six (13%) two (4%). The providing second MCV increased 27 (57%) 38 (81%), second-dose 25% 41%....
ABSTRACT The serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a study determine baseline rate and distribution before introduction in 1- 29-year old population Burkina Faso, group chosen for first vaccine. multiple cross-sectional was conducted one urban two rural districts Faso 2009. Every 3 months, oropharyngeal samples were collected from...
Abstract In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, reported increases in Neisseria meningitidis W, raising questions about whether these cases were a natural increase disease or resulted from replacement after PsA-TT introduction. We analyzed national surveillance data describe epidemiology of W and genotyped 61 isolates. total 5,807 meningitis through enhanced surveillance, which 2,353 (41%) laboratory...
Abstract Meningococcal meningitis remains a significant public health threat, especially in the African belt where Neisseria meningitidis serogroup A historically caused large-scale epidemics. With rollout of novel meningococcal conjugate vaccine (MACV) belt, World Health Organization recommended case-based surveillance to monitor MACV impact and epidemiology. In 2014, MenAfriNet consortium was established support strategic implementation 5 key countries: Burkina Faso, Chad, Mali, Niger,...
Background. An outbreak of serogroup C meningococcal disease that involved illicit drug users and their contacts occurred in Brooklyn, New York, during 2005 2006.
Abstract Background Meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017 into the routine childhood immunization schedule (at 15–18 months of age) Burkina Faso to help reduce meningococcal meningitis burden. MACV scheduled be co-administered with second dose measles-containing (MCV2), a already national schedule. One year following introduction MACV, an assessment conducted qualitatively examine health workers’ perceptions introduction, identify barriers uptake, and...
After successful meningococcal serogroup A conjugate vaccine (MACV) campaigns since 2010, Burkina Faso introduced MACV in March 2017 into the routine Expanded Programme for Immunization schedule at age 15-18 months, concomitantly with second-dose measles-containing (MCV2). We examined MCV2 coverage pre- and post-MACV introduction cohorts to describe observed changes regionally nationally.A nationwide household cluster survey of children 18-41 months was conducted 1 year after introduction....
The functionality and performance of public health programmes at all levels government play a critical role in preventing, detecting, mitigating responding to threats, including infectious disease outbreaks. Multiple concurrent outbreaks recent years, such as COVID-19, Ebola Zika, have highlighted the importance documenting lessons learnt from responses national global agencies. In February 2020, US Centers for Disease Control Prevention (CDC) Center Global Health (CGH) activated Measles...
To investigate the potential herd immunity effect of MenAfriVac, a new conjugate vaccine against serogroup A Neisseria meningitidis, multiple cross-sectional carriage study was conducted in three districts Burkina Faso 2009, yielding total 20 326 oropharyngeal samples. major challenge harmonisation operational procedures and ensuring reliability results. Here we describe laboratory quality control (QC) system that implemented. Laboratory analysis performed by local laboratories included...
Introduction: To achieve global and regional measles elimination objectives, the World Health Organization (WHO) recommends coverage of 95% or higher with two doses measles-containing vaccine. A second dose vaccine (MCV) is typically administered in year life after 12 months age. Methods: We reviewed WHO-UNICEF estimates national (WUENIC) for first MCV (MCV1 MCV2, respectively) calculated drop-out rates between MCV1 MCV2 countries WHO African Region. Results: From 2013 to 2023, estimated...
In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15-18 months, concomitantly with second dose of measles-containing (MCV2). One year after introduction, we assessed sources and content immunization information available caregivers explored motivations barriers that influence their decision seek for children.
Purpose of study: The aim this study was to determine the value real-time Polymerase Chain Reaction (rt-PCR) in routine surveillance pneumococcal meningitis Burkina Faso, compared standard methods culture, Gram stain and latex agglutination assay.Materiel methods: A total 385 specimens cerebrospinal fluid were analyzed by three bacteriological (Gram stain, assay, culture) Reaction.Results: Of these methods, 204 S. pneumoniae detected one or more methods. 36.4% (140/385) positive encapsulated...